Impact of sclerosing dacryoadenitis/sialadenitis on relapse during steroid therapy in patients with type 1 autoimmune pancreatitis

References

• Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64:3061–3067.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease. Lancet. 2015;385:1460–1471.
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Koike M, Tsuruta K, et al. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum Pathol. 1991;22:387–395.
   PubMed Web of Science ®Google Scholar
• Notohara K, Burgart LJ, Yadav D, et al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27:1119–1127.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Chari ST, Lerch MM, et al. Recent advances in autoimmune pancreatitis: type 1 and type 2. Gut. 2013;62:1373–1380.
   PubMed Web of Science ®Google Scholar
• Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicenter, international analysis. Gut. 2013;62:1771–1776.
   PubMed Web of Science ®Google Scholar
• Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–715.
   PubMed Web of Science ®Google Scholar
• Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol. 2009;104:2295–2306.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49:961–970.
   PubMed Web of Science ®Google Scholar
• Kubota K, Kamisawa T, Okazaki K, et al. Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients. J Gastroenterol. 2017;52:955–964.
   PubMed Web of Science ®Google Scholar
• Masamune A, Nishimori I, Kikuta K, et al. Randomized controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66:487–494.
   PubMed Web of Science ®Google Scholar
• Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas. 2011;40:352–358.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Okamoto A, Wakabayashi T, et al. Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome. Scand J Gastroenterol. 2008;43:609–613.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Egawa N, Inokuma S, et al. Pancreatic endocrine exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas. 2003;27:235–238.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Yoshiike M, Egawa N, et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology. 2005;5:238–240.
   Web of Science ®Google Scholar
• Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 2017;17:1–6.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–1507.
   PubMed Web of Science ®Google Scholar
• Huggett MT, Culver EL, Kumar M, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109:1675–1683.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Otsuki M. Study on steroid therapy for autoimmune pancreatitis. Annual reports of research committee of intractable pancreatic diseases supported by Ministry of Health, Labour and Welfare of Japan. 2008;137–144 (in Japanese).
   Google Scholar
• Miyazawa M, Takatori H, Shimakami T, et al. Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. PLoS One. 2017;12:e0188549.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Naitoh I, Nakazawa T, et al. Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: relapse, malignancy and side effect of steroid. Scand J Gastroenterol. 2015;50:1411–1418.
   PubMed Web of Science ®Google Scholar
• Kubota K, Iida H, Fujisawa T, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007;66:1142–1151.
   PubMed Web of Science ®Google Scholar
• Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139:140–148.
   PubMed Web of Science ®Google Scholar
• Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7:1089–1096.
   PubMed Web of Science ®Google Scholar
• Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56:1719–1724.
   PubMed Web of Science ®Google Scholar
• Maire F, Le Baleur Y, Rebours V, et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol. 2011;106:151–156.
   PubMed Web of Science ®Google Scholar
• Culver EL, Sadler R, Simpson D, et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UL cohort. Am J Gastroenterol. 2016;111:733–743.
   PubMed Web of Science ®Google Scholar
• Kubota K, Wada T, Kato S, et al. Highly active state of autoimmune pancreatitis with Mikulicz disease. Pancreas. 2010;39:e6–10.
   PubMed Web of Science ®Google Scholar
• Kuruma S, Kamisawa T, Tabata T, et al. Clinical characteristics of patients with autoimmune pancreatitis with or without Mikulicz’s disease and Mikulicz’s disease alone. Gut Liver. 2013;7:96–99.
   PubMed Web of Science ®Google Scholar
• Naitoh I, Nakazawa T, Ohara H, et al. Clinical significance of extrapancreatic lesions in autoimmune pancreatitis. Pancreas. 2010;39:e1–e5.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Nojima M, Takahashi H, et al. Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology. 2015;54:45–49.
   PubMed Web of Science ®Google Scholar